Cagrilintide vs Semaglutide
Cagrilintide is a long-acting amylin receptor agonist being developed primarily as part of the CagriSema combination, whilst semaglutide is an established selective GLP-1 receptor agonist. They target complementary appetite-regulating pathways — amylin and GLP-1 signalling respectively.
Last updated: 2026-03-13
Cagrilintide and semaglutide represent two distinct peptide-based approaches to metabolic regulation that target different, complementary hormonal pathways. Semaglutide, the well-established GLP-1 receptor agonist, is approved for type 2 diabetes and weight management. Cagrilintide, a long-acting amylin analogue developed by Novo Nordisk, is being developed primarily as part of the fixed-dose combination CagriSema (cagrilintide + semaglutide), though it has also been studied as monotherapy.
Amylin and GLP-1 are both hormones released in response to food intake, but they signal through different receptors and pathways. Combining their effects — as in CagriSema — may achieve greater appetite suppression and weight loss than either alone. Understanding the individual contributions of each component is essential for appreciating the rationale behind their combination.
**Important Note:** Semaglutide is an approved prescription medication. Cagrilintide is an investigational compound not yet approved for any indication. CagriSema is in Phase III clinical trials. This comparison is for educational purposes based on published research.
Quick Comparison Table
| Category | Cagrilintide | Semaglutide |
|---|---|---|
| Drug Class | Long-acting amylin receptor agonist | Selective GLP-1 receptor agonist |
| Hormone Mimicked | Amylin (co-secreted with insulin from beta cells) | GLP-1 (incretin hormone from L-cells) |
| Developer | Novo Nordisk | Novo Nordisk |
| Approval Status | Investigational (Phase III as CagriSema) | Approved globally (Ozempic, Wegovy, Rybelsus) |
| Monotherapy Weight Loss | ~10.8% (Phase II, 26 weeks, highest dose) | ~14.9% (STEP 1, 68 weeks, 2.4 mg) |
| CagriSema Weight Loss | ~22.7% (Phase III, combined with semaglutide) | ~15.8% as comparator arm (REDEFINE 1) |
| Half-Life | ~5 days (fatty acid acylation) | ~7 days (fatty acid acylation) |
| Primary Mechanism | Area postrema/brainstem appetite centres; gastric emptying delay | Hypothalamic appetite centres; gastric emptying delay; insulinotropic |
Mechanism of Action Comparison
Cagrilintide
Cagrilintide — Long-Acting Amylin Receptor Agonist:
Cagrilintide is an acylated analogue of amylin, a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. Fatty acid acylation extends its half-life to approximately 5 days (versus minutes for native amylin), enabling once-weekly dosing.
Key mechanisms include: - **Area postrema activation** — amylin receptors in the area postrema (a brainstem circumventricular organ) mediate satiety signalling distinct from GLP-1 pathways. This represents a complementary appetite suppression mechanism. - **Gastric emptying delay** — amylin slows gastric emptying, prolonging nutrient absorption and enhancing post-prandial satiety. This effect is additive with GLP-1-mediated gastric slowing. - **Glucagon suppression** — amylin suppresses post-prandial glucagon secretion, contributing to improved glycaemic control. - **Central appetite effects** — amylin signalling influences hedonic and homeostatic feeding behaviours through brainstem and hypothalamic pathways that are distinct from, but interact with, GLP-1 circuits.
Unlike pramlintide (the only approved amylin analogue), cagrilintide's long half-life enables weekly rather than thrice-daily dosing.
Semaglutide
Semaglutide — Selective GLP-1 Receptor Agonist:
Semaglutide activates GLP-1 receptors widely expressed in the brain, pancreas, GI tract, and cardiovascular system: - **Hypothalamic appetite suppression** — GLP-1 receptors in the arcuate nucleus and paraventricular nucleus mediate powerful appetite reduction through POMC neurone activation and AgRP/NPY neurone inhibition. - **Gastric emptying delay** — slowing of gastric motility contributes to post-prandial satiety. - **Glucose-dependent insulin secretion** — enhances beta-cell insulin release only when glucose is elevated, minimising hypoglycaemia risk. - **Glucagon suppression** — reduces hepatic glucose output in the fed state. - **Food reward modulation** — emerging evidence suggests semaglutide affects mesolimbic reward circuitry, reducing cravings and food preoccupation. - **Cardiovascular effects** — anti-inflammatory and anti-atherosclerotic properties contributing to CV risk reduction.
Clinical Trial Evidence
Cagrilintide Clinical Studies
Design: Meta-analysis
Participants: 4,419 participants
CagriSema therapy was associated with superior weight reduction compared with semaglutide or placebo. In conclusion, CagriSema achieves greater weight loss than semaglutide or placebo but increases gastrointestinal adverse events, warranting careful tolerability monitoring and longer-term data.
View study — PubMed 41759565Design: Meta-analysis
Participants: 3,545 participants
Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dual-agonist therapy for obese patients.
View study — PubMed 41834765Design: Meta-analysis
Tirzepatide 15 mg and CagriSema achieve the greatest weight reduction, including ≥ 20% body weight loss. Gastrointestinal adverse events rise with treatment intensity, while serious adverse events remain comparable to placebo. These findings support dual-pathway and combination incretin therapies as preferred options for patients requiring substantial weight loss.
View study — PubMed 42207966Design: Meta-analysis
Participants: 246 participants
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss.
View study — PubMed 38286487Semaglutide Clinical Studies
Design: Meta-analysis
Participants: 2,258 participants
Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.
View study — PubMed 39719170Design: Meta-analysis
Participants: 2,372 participants
In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.
View study — PubMed 40186344Design: Meta-analysis
Participants: 246 participants
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss.
View study — PubMed 38286487Design: Meta-analysis
Participants: 28 participants
Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.
View study — PubMed 38613667Benefits Comparison
Cagrilintide Unique Benefits
- Activates a complementary appetite suppression pathway (amylin) not targeted by GLP-1 agonists
- When combined with semaglutide (CagriSema), achieves ~22.7% weight loss — approaching surgical levels
- May provide incremental benefit in patients who plateau on GLP-1 monotherapy
- Long half-life enables weekly dosing (a significant improvement over pramlintide's thrice-daily injections)
- Brainstem-mediated satiety represents a mechanistically distinct approach to appetite control
Shared Benefits
- Clinically meaningful weight loss superior to older pharmacotherapies
- Improved glycaemic control in type 2 diabetes
- Reduction in cardiometabolic risk factors
- Once-weekly administration schedule
- Both developed by Novo Nordisk with complementary pharmacology
- Gastric emptying delay contributing to satiety
Semaglutide Unique Benefits
- Extensively validated with the largest clinical evidence base of any anti-obesity medication
- Proven cardiovascular risk reduction (SELECT trial)
- Multiple approved indications and formulations (injectable and oral)
- Established safety profile with post-marketing surveillance data
- Available globally through legitimate healthcare channels
- Insurance coverage and access pathways established in many countries
Research & Evidence
Cagrilintide Research
Cagrilintide's evidence base is currently limited to Phase II monotherapy data and Phase III CagriSema combination data. The REDEFINE programme encompasses multiple Phase III trials evaluating CagriSema across different populations including obesity, type 2 diabetes, and specific comorbidity groups. Cagrilintide monotherapy has not been pursued as a standalone commercial programme.
Semaglutide Research
Semaglutide has one of the most robust clinical evidence programmes in metabolic medicine. The STEP programme (weight management), SUSTAIN programme (diabetes), SELECT trial (cardiovascular outcomes), FLOW trial (kidney outcomes), and numerous additional studies spanning thousands of patients and multiple years provide comprehensive efficacy and safety data across diverse populations and indications.
Head-to-Head Analysis
The REDEFINE programme includes semaglutide 2.4 mg as an active comparator arm, providing direct comparison data. REDEFINE 1 showed CagriSema superiority over semaglutide monotherapy for weight loss (~22.7% vs ~15.8%), confirming the incremental benefit of adding amylin pathway activation to GLP-1 agonism.
Protocol Comparison
Cagrilintide Protocol
Cagrilintide (Investigational): Studied at doses up to 4.5 mg as monotherapy and 2.4 mg in the CagriSema combination. Administered as a once-weekly subcutaneous injection. Dose escalation schedules have been employed to manage GI tolerability.
NOT available outside clinical trials. These are investigational protocols.
Semaglutide Protocol
Semaglutide (Approved): For weight management (Wegovy): initiated at 0.25 mg weekly, escalated monthly over 16 weeks to the maintenance dose of 2.4 mg weekly. Subcutaneous injection in abdomen, thigh, or upper arm. For T2D (Ozempic): maximum dose 2.0 mg weekly. Oral (Rybelsus): 3, 7, or 14 mg daily.
Prescription medication requiring medical supervision.
Combined Use
CagriSema IS the combined use of cagrilintide and semaglutide — a fixed-dose combination delivering both peptides in a single weekly injection. Phase III data demonstrate that the combination achieves significantly greater weight loss than either component alone, validating the complementary mechanism hypothesis. CagriSema regulatory submissions are anticipated following Phase III programme completion.
Safety Profiles
Cagrilintide Safety
Cagrilintide Safety Profile (Limited): Phase II monotherapy data show primarily GI side effects: nausea, vomiting, diarrhoea. In the CagriSema combination, GI adverse events were broadly comparable to semaglutide monotherapy, suggesting the combination does not dramatically worsen tolerability. Long-term safety data are not yet available. Theoretical concerns relate to amylin's effects on gastric motility and potential interactions with insulin therapy.
Semaglutide Safety
Semaglutide Safety Profile (Established): Well-characterised through extensive trials and post-marketing surveillance. Common: nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%). Rare: pancreatitis, gallbladder disease, thyroid C-cell concerns (rodent studies). Contraindicated with MTC/MEN2 history. Long-term safety data from SELECT (>3 years median follow-up) support a favourable benefit-risk profile.
The Verdict: When to Choose Which?
Choose Cagrilintide When:
- Your clinician determines that amylin pathway activation may provide additional benefit beyond GLP-1 agonism (when CagriSema is approved)
- You have not achieved adequate weight loss with GLP-1 monotherapy and the dual pathway may offer incremental efficacy
- You are eligible for a CagriSema or cagrilintide clinical trial
Choose Semaglutide When:
- You need an established, approved medication available now
- Cardiovascular risk reduction is a primary treatment goal
- An oral formulation is preferred (Rybelsus available for diabetes)
- Long-term safety data and clinical experience are priorities
- You require established insurance coverage and access pathways
Consider Combining When:
- CagriSema IS the combination of cagrilintide and semaglutide — the entire clinical development programme is based on their complementary use
- Phase III data show the combination achieves ~22.7% weight loss versus ~15.8% with semaglutide alone
- If approved, CagriSema would be administered as a single weekly injection containing both peptides
Frequently Asked Questions
Conclusion
Cagrilintide and semaglutide represent complementary approaches to appetite regulation through different hormonal pathways. Semaglutide is the established standard of care with unparalleled clinical evidence and proven cardiovascular benefits. Cagrilintide's primary value lies not as monotherapy but as the second component of CagriSema, where the addition of amylin pathway activation to GLP-1 agonism produces near-surgical levels of weight loss. For current use, semaglutide remains the evidence-based choice. CagriSema, if approved, may represent the next standard of care for patients requiring maximum pharmacological weight loss.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Cagrilintide nor Semaglutide is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.